Status | Study |
Recruiting |
Study Name: FIBrinogen REplenishment in Surgery Condition: Deficiency; Fibrinogen, Acquired Date: 2017-01-27 Interventions: Drug: Octafibrin Octafibrin wi |
Recruiting |
Study Name: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A Condition: Hemophilia A Date: 2016-12-21 Interventions: Drug: Emicizumab Emicizumab will be administered according to dose and schedule described in respective |
Recruiting |
Study Name: A Gene Transfer Study for Hemophilia A Condition: Hemophilia A Date: 2016-12-16 Interventions: Genetic: SPK-8011 A novel, bio-engineered, recombinant adeno-associated viral vector carrying human fact |
Active, not recruiting |
Study Name: Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe Condition: Factor VIII Deficiency, Congenital Factor 8 Deficiency, Congenital Date: 2016-11-30 |
Recruiting |
Study Name: Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products Condition: Hemophilia A Date: 2016-11-24 Interventions: Drug: efmoroctocog alfa extend |
Enrolling by invitation |
Study Name: A Study of ProMetic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia Condition: Hypoplasminogenemia Date: 2016-02-12 Interventions: Biological: Plasminogen (human) intravenous ProMetic Plasminogen(human) intravenous |
Completed |
Study Name: A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency Condition: Type I Plasminogen Deficiency Hypoplasminogenemia Date: 2014-12-04 Interventions: Biological: Plasminogen (Human) Intravenous Plasma-derived purified plasminogen formulated for intraveno |
Withdrawn |
Study Name: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B Condition: Hemophilia B Date: 2013-11-14 Interventions: Biological: IB1001 Prophylaxis (during Treatment and Conti |
Terminated |
Study Name: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A Condition: Hemophilia A Date: 2011-09-13 Interventions: Biological: OBI-1 intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment |
Completed |
Study Name: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A Condition: Hemophilia A Date: 2010-08-06 Interventions: Biological: OBI-1 Intravenous infusion |